Articles by Andrew Moreno
This agent which has newly received an ODD for MDS recalibrates the immune system to attack hematological and solid tumors.
Some major themes for practice include identifying patients at risk for early progression and emphasis on quality of life.
Overall survival was also greater in the study comparing the treatments in ALL, AML, MDS, and mixed-phenotype acute leukemia.
Investigators observed that overall treatment has improved but hospitalizations and other events indicate unaddressed need.
The Myelofibrosis Symptom Assessment Form is the only instrument currently available for evaluating myelofibrosis symptoms.
Azercabtagene zapreleucel applies a novel approach of combining lymphodepletion chemotherapy with interleukin-2.
In a phase 2 trial the hepcidin mimetic increased hematocrit control while reducing phlebotomy and patient-reported symptoms.
A study found maximum tumor diameter and lack of radiotherapy with chemotherapy are independent risk factors for HL relapse.
Challenges exist in translating individual patients' risk into risk groups for use in everyday practice or a trial's design.
A phase 2 study sought to determine if use of nivolumab instead of vinblastine in the test combination improved safety.
A study found limits to the prediction utility of thrombosis history in patients with PV and pulmonary hypertension risk.
The experts focused on cilta-cel when comparing the three FDA-approved treatments' efficacies, toxicities, and availability.
New data on immune thrombocytopenia were most prominent but Meeting coverage ranged over several forms of the disease.
Measurable residual disease has a prominent role in risk assessment, prognosis, and management decisions in T-ALL and B-ALL.
A study finds shortened overall survival with thrombotic events more severe in arterial thrombosis than venous thrombosis.
This orally available, selective inhibitor of XPO1 is the first agent of its kind to receive commercialization approval.
In a phase 1/2 trial the oral BCR-ABL1 TK inhibitor had effect even in patients with ponatinib-resistant disease.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.
Linvoseltamab continues to be clinically evaluated as monotherapy and in combination therapy for relapsed or refractory MM.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.